Soybean isoflavone treatment induces osteoblast differentiation and proliferation by regulating analysis of Wnt/β-catenin pathway

Fang, Yu; Z, Liu; Tong, Zhihong; Zhao, Zhengnan; Liang, Haidong

doi:10.1016/j.gene.2015.07.054

Cited by 34 publications

(26 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is both in vivo and in vitro evidence that soy isoflavones alter expression of genes encoding proteins involved in osteoclast and osteoblast differentiation, proliferation, and activity. In vivo, isoflavones increase osteoblast differentiation and proliferation by activating Smad(s) ( Zhang et al, 2012 ), decrease RANKL levels ( Yu et al, 2015 ), and increase osteoblast OPG expression ( Yu et al, 2015 ). Soy isoflavones also increase expression of β-catenin and Wnts 3a and 7b in primary osteoblasts ( Yu et al, 2015 ).…”

Section: Discussionmentioning

confidence: 99%

“…In vivo, isoflavones increase osteoblast differentiation and proliferation by activating Smad(s) ( Zhang et al, 2012 ), decrease RANKL levels ( Yu et al, 2015 ), and increase osteoblast OPG expression ( Yu et al, 2015 ). Soy isoflavones also increase expression of β-catenin and Wnts 3a and 7b in primary osteoblasts ( Yu et al, 2015 ). Interestingly, osteoblasts have a membrane ER that binds daidzein and is structurally similar to ER-β, but not ER-α ( de Wilde et al, 2006 ), which is expected as isoflavones preferentially bind ER-β.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Soy protein improves tibial whole-bone and tissue-level biomechanical properties in ovariectomized and ovary-intact, low-fit female rats

et al. 2018

View full text Add to dashboard Cite

BackgroundOsteoporosis and related fractures, decreased physical activity, and metabolic dysfunction are serious health concerns for postmenopausal women. Soy protein might counter the negative effects of menopause on bone and metabolic health due to the additive or synergistic effects of its bioactive components.ObjectiveTo evaluate the effects of ovariectomy (OVX) and a soy-protein diet (SOY) on bone outcomes in female, low-capacity running (LCR) rats selectively bred for low aerobic fitness as a model of menopause.MethodsAt 27 weeks of age, LCR rats (N = 40) underwent OVX or sham (SHAM) surgery and were randomized to one of two isocaloric and isonitrogenous plant-protein-based dietary treatments: 1) soy-protein (SOY; soybean meal); or, 2) control (CON, corn-gluten meal), resulting in four treatment groups. During the 30-week dietary intervention, animals were provided ad libitum access to food and water; body weight and food intake were measured weekly. At completion of the 30-week intervention, body composition was measured using EchoMRI; animals were fasted overnight, euthanized, and blood and hindlimbs collected. Plasma markers of bone formation (osteocalcin, OC; N-terminal propeptide of type I procollagen, P1NP) and resorption (tartrate-resistant acid phosphatase, TRAP5b; C-terminal telopeptide of type I collagen, CTx) were measured using ELISA. Tibial trabecular microarchitecture and cortical geometry were evaluated using μCT; and torsional loading to failure was used to assess cortical biomechanical properties. Advanced glycation end-product (AGE) content of the femur was measured using a fluorimetric assay, and was expressed relative to collagen content measured by a colorimetric OH-proline assay. Two-factor ANOVA or ANOVCA was used to test for significant main and interactive effects of ovarian status (OV STAT: OVX vs. SHAM) and DIET (SOY vs. CON); final body weight was included as a covariate for body-weight-dependent cortical geometry and biomechanical properties.ResultsOVX had significantly greater CTx than SHAM; SOY did not affect bone turnover markers. OVX adversely affected trabecular microarchitecture as evidenced by reduced BV/TV, trabecular thickness (Tb.Th), trabecular number (Tb.N), and connectivity density (Conn.D), and by increased trabecular separation (Tb.Sp) and structural model index (SMI). SOY increased BV/TV only in ovary-intact animals. There was no effect of OVX or SOY on tibial cortical geometry. In SHAM and OVX rats, SOY significantly improved whole-bone strength and stiffness; SOY also increased tissue-level stiffness and tended to increase tissue-level strength (p = 0.067). There was no effect of OVX or SOY on AGE content.ConclusionSoy protein improved cortical bone biomechanical properties in female low-fit rats, regardless of ovarian hormone status.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Soy protein improves tibial whole-bone and tissue-level biomechanical properties in ovariectomized and ovary-intact, low-fit female rats

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Genistein can promote the growth of human bone marrow mesenchymal stem cells in vitro [9] and inhibit osteoclasts formation of bone marrow cells from the methotrexate-treated rats [36]. Soy isoflavone mixtures at dose levels of 0.1–0.3 mol/L can enhance the growth of the osteoblasts isolated from skull bones of neonatal rats [37]. In the present study, genistein was also capable of promoting the growth of the osteoblasts (hFOB1.19 cells) at lower dose levels (e.g., 2.5 μg/L), evidencing its 17β-estradiol-like effect once more.…”

Section: Discussionmentioning

confidence: 99%

The Cooperative Effect of Genistein and Protein Hydrolysates on the Proliferation and Survival of Osteoblastic Cells (hFOB 1.19)

Wang

Zhao

2016

Molecules

View full text Add to dashboard Cite

Chum salmon skin gelatin, de-isoflavoned soy protein, and casein were hydrolyzed at two degrees of hydrolysis. Genistein, the prepared hydrolysates, and genistein-hydrolysate combinations were assessed for their proliferative and anti-apoptotic effects on human osteoblasts (hFOB 1.19) to clarify potential cooperative effects between genistein and these hydrolysates in these two activities. Genistein at 2.5 µg/L demonstrated the highest proliferative activity, while the higher dose of genistein inhibited cell growth. All hydrolysates promoted osteoblast proliferation by increasing cell viability to 102.9%-131.1%. Regarding etoposide-or NaF-induced osteoblast apoptosis, these hydrolysates at 0.05 g/L showed both preventive and therapeutic effects against apoptosis. In the mode of apoptotic prevention, the hydrolysates decreased apoptotic cells from 32.9% to 15.2%-23.7% (etoposide treatment) or from 23.6% to 14.3%-19.6% (NaF treatment). In the mode of apoptotic rescue, the hydrolysates lessened the extent of apoptotic cells from 15.9% to 13.0%-15.3% (etoposide treatment) or from 13.3% to 10.9%-12.7% (NaF treatment). Gelatin hydrolysates showed the highest activities among all hydrolysates in all cases. All investigated combinations (especially the genistein-gelatin hydrolysate combination) had stronger proliferation, apoptotic prevention, and rescue than genistein itself or their counterpart hydrolysates alone, suggesting that genistein cooperated with these hydrolysates, rendering greater activities in osteoblast proliferation and anti-apoptosis.

show abstract

“…Um estudo mostrou que as isoflavonas da soja promovem a proliferação e diferenciação dos osteoblastos, diminuindo acentuadamente os níveis RANKL, aumentando os níveis de OPG em células osteoblásticas resultando em ativação da via β-catenina/ Wnt (YU et al, 2015). A associação das isoflavonas de soja com β-caroteno também mostrou benefício para a formação óssea com manutenção de um equilíbrio positivo na remodelação óssea, por indução da diferenciação de osteoblastos (NISHIDE et al, 2015).…”

Section: As Plantas Medicinais Que Podem Ser Utilizadas Para Tratamenunclassified

Caracterização Das Plantas Medicinais E Medicamentos Fitoterápicos Para Tratamento Da Osteoporose Utilizados No Brasil

Marques

Lima

Andreotti

et al. 2016

Arq. Ciênc. Saúde Unipar

View full text Add to dashboard Cite

Caracterização das plantas medicinais e medicamentos fitoterápicos para tratamento da osteoporose utilizados no Brasil. Arq. Cienc. Saúde UNIPAR, Umuarama, v. 20, n. 3, p, 183-188, set./dez. 2016. RESUMO:A osteoporose é caracterizada por desordem do sistema esquelético caracterizada por baixa massa óssea e deteriorização da microarquitetura do tecido ósseo levando a fragilidade óssea com aumento da suscetibilidade a fraturas. Considerada a doença osteometabólica mais comum, de distribuição global, pode comprometer ambos os sexos, diferentes idades ou raças. As consequências relacionadas a essas doenças são as fraturas vertebrais verificadas em aproximadamente 20% das mulheres acima de 65 anos em pós-menopausa. Além disso, a consequência dessa fragilidade óssea pode levar a consequências graves como dor, deformidades, sequelas, restrições motoras e morte precoce, portanto, associada com alta morbi/mortalidade. Desta forma, sabendo que as medicações utilizadas para o tratamento da osteoporose não são isentas de risco (por exemplo, aumento do risco de tromboses, câncer de mama/ ovário/ endométrio, lesões musculares, entre outras), foi realizado uma revisão bibliográfica com o intuito de avaliar se existem plantas medicinais que possam ter efeitos ósseo protetores com menor número de efeitos adversos em relação aos fármacos sintéticos. Em síntese, verificou-se que os fármacos sintéticos podem acarretar prejuízos à saúde do paciente a longo prazo e que as plantas medicinais ou fitoterápicos utilizadas no Brasil apresentam estudos científicos com menores efeitos colaterais e, portanto, são uma alternativa viável para o tratamento e prevenção da osteoporose, visto que a Politica Nacional de Práticas Integrativas e Complementares na Atenção Básica sustenta esta tendência mediante subsídios como a Farmacopeia Brasileira e o Memento Fitoterápico. PALAVRAS-CHAVE: Brasil. Fitoterapia. Medicamentos Fitoterápicos. Osteoporose. CHARACTERIZATION OF MEDICINAL PLANTS AND HERBAL MEDICINES FOR THE TREATMENT OF OSTEOPOROSIS USED IN BRAZILABSTRACT: Osteoporosis is characterized by skeletal system disorder, consisting of low bone mass and deterioration of the microarchitecture of the bone tissue, leading to bone fragility with increased susceptibility to fractures. Considered the most common osteometabolic disease worldwide, it affects both sexes, different ages and races. The consequences of these diseases are vertebral fractures in approximately 20% of postmenopausal women over 65 years of age. In addition, the consequence of this bone fragility may lead to serious consequences, such as pain, deformities, sequelae, motor restrictions and early death, being therefore associated with high morbidity/mortality. Therefore, knowing the medication used in the treatment of osteoporosis are not free of risk (for example, increased risk of thrombosis, breast/ovarian/endometrial cancer, muscle injuries, among others), a bibliographical review was made with the intent of evaluating whether there are medicinal plants that may have protective ef...

show abstract

Soybean isoflavone treatment induces osteoblast differentiation and proliferation by regulating analysis of Wnt/β-catenin pathway

Cited by 34 publications

References 52 publications

Soy protein improves tibial whole-bone and tissue-level biomechanical properties in ovariectomized and ovary-intact, low-fit female rats

Soy protein improves tibial whole-bone and tissue-level biomechanical properties in ovariectomized and ovary-intact, low-fit female rats

The Cooperative Effect of Genistein and Protein Hydrolysates on the Proliferation and Survival of Osteoblastic Cells (hFOB 1.19)

Caracterização Das Plantas Medicinais E Medicamentos Fitoterápicos Para Tratamento Da Osteoporose Utilizados No Brasil

Contact Info

Product

Resources

About